111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY. (April 2015) - Mufti, G.J.; Best, S.; Lea, N.; Hellstrom-Lindberg, E.; Silverman, L.R.; Garcia-Manero, G.; Azarnia, N.; Petrone, M.E.; Snyder, B.R.; Gohring, G.